PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33673187-4 2021 CBE co-treatment with rosuvastatin attenuated statin-mediated PCSK9 expression, and further increased LDLR. Rosuvastatin Calcium 22-34 proprotein convertase subtilisin/kexin type 9 Homo sapiens 62-67 31448346-10 2019 Conclusions: The addition of metformin to ongoing rosuvastatin therapy did not significantly affect serum lipid levels, but stabilized the level of circulating PCSK9, compared with the group without metformin treatment. Rosuvastatin Calcium 50-62 proprotein convertase subtilisin/kexin type 9 Homo sapiens 160-165 30741744-9 2019 High-dose atorvastatin and rosuvastatin induced similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similarly increased in high-density lipoprotein cholesterol and PCSK9 levels (P>0.05). Rosuvastatin Calcium 27-39 proprotein convertase subtilisin/kexin type 9 Homo sapiens 192-197 30741744-10 2019 CONCLUSION: We showed that atorvastatin and rosuvastatin treatment regimens have comparable effects on lipid parameters and PCSK9 levels in ACS patients. Rosuvastatin Calcium 44-56 proprotein convertase subtilisin/kexin type 9 Homo sapiens 124-129 27878791-5 2016 Because of the relatively high cost of these new therapies, physicians need to justify the use of PCSK9 inhibitors by demonstrating that their high-risk patients" LDL-C levels have remained high (1) despite a well-conducted, but insufficiently effective high-intensity statin therapy (e.g. rosuvastatin 10-20 mg or atorvastatin 40-80 mg), or (2) in the event of the patient developing side effects, in particular severe SAMS, during treatment with at least three statins. Rosuvastatin Calcium 290-302 proprotein convertase subtilisin/kexin type 9 Homo sapiens 98-103 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 proprotein convertase subtilisin/kexin type 9 Homo sapiens 190-195 21262787-5 2011 We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Rosuvastatin Calcium 25-37 proprotein convertase subtilisin/kexin type 9 Homo sapiens 128-133 21262787-5 2011 We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Rosuvastatin Calcium 53-65 proprotein convertase subtilisin/kexin type 9 Homo sapiens 128-133 28616272-0 2017 The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. Rosuvastatin Calcium 58-70 proprotein convertase subtilisin/kexin type 9 Homo sapiens 86-91 28616272-5 2017 METHODS: This study involves patients with stable angina and aims to explore and clarify the short-term impacts of rosuvastatin and ezetimibe, alone or in combination, on circulating PCSK9. Rosuvastatin Calcium 115-127 proprotein convertase subtilisin/kexin type 9 Homo sapiens 183-188 28616272-11 2017 Rosuvastatin therapy (alone or combined with ezetimibe) caused significant rise in circulating PCSK9. Rosuvastatin Calcium 0-12 proprotein convertase subtilisin/kexin type 9 Homo sapiens 95-100 22065156-3 2012 METHODS: We measured plasma PCSK9 concentrations by ELISA at baseline and at 1 year in 500 men and 500 women participating in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial that randomly allocated participants to rosuvastatin 20 mg daily or placebo. Rosuvastatin Calcium 211-223 proprotein convertase subtilisin/kexin type 9 Homo sapiens 28-33 22065156-7 2012 In contrast, the rosuvastatin increased PCSK9 by 35% in women [101 (82-117) ng/mL] and 28% in men [89 (71-109) ng/mL] (P<0.0001). Rosuvastatin Calcium 17-29 proprotein convertase subtilisin/kexin type 9 Homo sapiens 40-45 22065156-8 2012 Among those allocated to rosuvastatin, greater reductions in LDL-C were associated with greater increases in PCSK9 on both absolute and relative scales (r=-0.15, P<0.0005). Rosuvastatin Calcium 25-37 proprotein convertase subtilisin/kexin type 9 Homo sapiens 109-114 22065156-10 2012 CONCLUSIONS: In this randomized trial, rosuvastatin increased plasma concentration of PCSK9 in proportion to the magnitude of LDL-C reduction; the LDL-C response to statin could not be inferred by PCSK9 concentrations. Rosuvastatin Calcium 39-51 proprotein convertase subtilisin/kexin type 9 Homo sapiens 86-91 21262787-0 2011 Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Rosuvastatin Calcium 36-48 proprotein convertase subtilisin/kexin type 9 Homo sapiens 81-86